| Identification | Back Directory | [Name]
rel-(5bR,7aS,14aS)-5b,6,7,7a,8,13,14,14a,16,17-Decahydro-7a,10-dimethoxy-5H-indolo[3′,2′:8,9]quinolizino[4,3-b]carbazole | [CAS]
2708270-99-7 | [Synonyms]
SIMR3030
rel-(5bR,7aS,14aS)-5b,6,7,7a,8,13,14,14a,16,17-Decahydro-7a,10-dimethoxy-5H-indolo[3′,2′:8,9]quinolizino[4,3-b]carbazole
5H-Indolo[3′,2′:8,9]quinolizino[4,3-b]carbazole, 5b,6,7,7a,8,13,14,14a,16,17-decahydro-7a,10-dimethoxy-, (5bR,7aS,14aS)-rel- | [Molecular Formula]
C27H29N3O2 | [MOL File]
2708270-99-7.mol | [Molecular Weight]
427.54 |
| Hazard Information | Back Directory | [Uses]
SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 μg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice[1]. | [in vivo]
SIMR3030 (25, 50, 100 mg/kg; I.p.; daily for 14 days) exhibits a satisfactory safety profile in experimental mice model[1]. | Animal Model: | 18-25 g, adult female Balb/c mice[1] | | Dosage: | 25, 50, 100 mg/kg | | Administration: | I.p.; daily for 14 days | | Result: | Showed no signs of toxicity or weight loss were noticed during 12.5 and 25 mg/kg multiple-dose studies for 14 days, no signs of toxicity or weight loss were noticed during 12.5 and 25 mg/kg multiple-dose studies for 14 days. |
| [References]
[1] Hersi F, et al. Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19. Eur J Med Chem. 2023 Jun 5;254:115380. DOI:10.1016/j.ejmech.2023.115380 |
|
|